Clinical trial
A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2
NCT02733159 is registered in ClinicalTrials.gov with University of Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2
- Lead sponsor
- University of Birmingham
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 4, 2017
- Completion date
- February 5, 2024
- Enrollment
- 62 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.